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Uncertainty exists on the prevalence of glucose intolerance in women with a recent diagno-
sis of gestational diabetes (GDM) based on a two-step screening strategy and the 2013
World Health Organization (WHO) criteria. Our aim was to evaluate the uptake of postpar-
tum screening, the prevalence and the risk factors for glucose intolerance in women with a
recent history of GDM.
Methods
Retrospective analysis of the medical records of women with a recent history of GDM diag-
nosed in a universal two-step screening strategy with the 2013WHO criteria. All women
with a history of GDM are advised to undergo a 75g oral glucose tolerance test (OGTT)
around 12 weeks postpartum. Indices of insulin sensitivity (the Matsuda index and the recip-
rocal of the homeostasis model assessment of insulin resistance, 1/HOMA-IR) and an
index of beta-cell function, the Insulin Secretion-Sensitivity Index-2 (ISSI-2) were calculated
based on the OGTT postpartum. Multivariable logistic regression was used to adjust for
confounders such as age, BMI, ethnicity and breastfeeding.
Results
Of the 191 women with GDM, 29.3% (56) did not attend the scheduled postpartum OGTT.
These women had a higher BMI (28.6 ±6.8 vs. 26.2 ± 5.6, p = 0.015), were more often from
an ethnic minority (EM) background (41.1% vs. 25.2%, p = 0.029) and smoked more often
during pregnancy (14.3% vs. 2.2%, p = 0.001) than women who attended the OGTT post-
partum. Of all women (135) who received an OGTT postpartum, 42.2% (57) had prediabe-
tes (11.9% impaired fasting glucose, 24.4% impaired glucose tolerance and 5.9% both
impaired fasting and impaired glucose tolerance) and 1.5% (2) had overt diabetes. Com-
pared to women with a normal OGTT postpartum, women with glucose intolerance were
older (32.5±4.3 vs. 30.8±4.8 years, p = 0.049), were more often obese (34.5% vs. 17.3%,
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p = 0.023), were more often from an EM background (33.9% vs. 18.4%, p = 0.040), less
often breastfed (69.5% vs. 84.2%, p = 0.041) and had more often an abnormal fasting gly-
caemia at the time of the OGTT in pregnancy (55.6% vs. 37.3%, p = 0.040). In the multivari-
able logistic regression, an EM background [OR = 2.76 (1.15–6.62), p = 0.023] and the
HbA1c level at the time of the OGTT in pregnancy [OR = 4.78 (1.19–19.20), p = 0.028]
remained significant predictors for glucose intolerance postpartum. Women with glucose
intolerance postpartum had a similar insulin sensitivity [Matsuda index 0.656 (0.386–1.224)
vs. 0.778 (0.532–1.067), p = 0.709; 1/HOMA-IR 0.004 (0.002–0.009) vs. (0.004–0.003–
0.007), p = 0.384] but a lower beta-cell function compared to women with a normal OGTT
postpartum, remaining significant after adjustment for confounders [ISSI-2 1.6 (1.2–2.1) vs.
1.9 (1.7–2.4),p = 0.002].
Conclusions
Glucose intolerance is very frequent in early postpartum in women with GDM based on the
2013WHO criteria in a two-step screening strategy and these women have an impaired
beta-cell function. Nearly one third of women did not attend the scheduled OGTT postpar-
tum and these women have an adverse risk profile. More efforts are needed to engage and
stimulate women with GDM to attend the postpartum OGTT.
Introduction
Gestational diabetes (GDM) was historically defined as ‘any degree of glucose intolerance with
onset or first recognition during pregnancy’ [1]. The incidence of GDM is rising globally and it
represents an important modifiable risk factor for adverse pregnancy outcomes such as macro-
somia and preeclampsia [2,3]. There is since long lack of uniformity in the approach to screen-
ing and diagnosis of GDM. Since 2010, the ‘International Association of Diabetes and
Pregnancy Study Groups’ (IADPSG) recommends a one-step screening strategy with the
2-hour 75g oral glucose tolerance test (OGTT) using stricter criteria to diagnose GDM [4].
Using the IADPSG criteria, GDM affects 9–25% of pregnancies [5]. Since 2013 the World
Health Organization (WHO) also advises the use of the IADPSG criteria for the diagnosis of
GDM [6]. The IADPSG criteria for the diagnosis of GDM are therefore now commonly called
the 2013 WHO criteria for GDM. In the past, research into whether women with GDM suf-
fered from postpartum type 2 diabetes (T2DM) focused on women with GDM diagnosed by
the 1999 WHO or the Carpenter and Coustan criteria. Using these criteria, GDM women were
found to be seven times more likely to develop T2DM than non-GDM women [7]. The use of
the 2013 WHO criteria for GDM results in a greater proportion of women diagnosed with
GDM but there is uncertainty on the risk of women who have had mild GDM to develop
T2DM postpartum. Timely detection of glucose intolerance postpartum is important since
progression to T2DM can be reduced with 40% by lifestyle intervention programmes and met-
formin therapy post-pregnancy [8]. Currently there are few data on the risk for persistent glu-
cose intolerance in early postpartum in women with GDM diagnosed by an universal two-step
screening strategy and the 2013 WHO criteria. Studies are therefore needed that address this
deficiency by including a postpartum OGTT in women diagnosed with GDM to establish early
post-delivery (pre)diabetes status. The aim of our study was therefore to evaluate the uptake of
our current screening strategy postpartum, the prevalence and the risk factors for glucose
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intolerance based on a OGTT three months postpartum in women with GDM detected by a
universal two-step screening strategy with the 2013 WHO criteria.
Materials and Methods
Retrospective analysis of the electronic medical records of the University Hospital UZ Leuven
in Belgium, from 01-03-2014 till 08-02-2016 of women with a recent history of GDM diag-
nosed with the 2013 WHO criteria. The study was approved by the Institutional Review Board
of UZ Leuven (S58329). The study was conducted according to the principles expressed in the
Declaration of Helsinki. Due to the retrospective nature of the study there was no need for
informed consent from the participants (the data were analyzed anonymously) as in compli-
ance with the Belgian Law of December 8,1992 on the protection of privacy and the Belgian
Law of August 22, 2002 on the rights of the patient.
Approximately 2400 women are delivered annually at our hospital. The background preva-
lence of T2DM in Belgium is 6.5% [9]. In the general adult population 28% of women are over-
weight and 13% are obese [10]. Leuven is a medium size city in the region of Flanders and has
a population with a rather low background number of women from ethnic minorities (EM)
(10.9%) [10]. Accurate data on the prevalence of GDM are lacking in Belgium and the current
practice for screening for GDM varies across different centers [11]. Women are not yet univer-
sally screened for overt diabetes at first prenatal visit in our hospital.
Screening for GDM
Until March 2014, a 100g 3-h OGTT with the Carpenter and Coustan criteria was used for the
diagnosis of GDM in our hospital. Since March 2014, we use a 2-h 75g OGTT with the 2013
WHO criteria for the diagnosis of GDM. However, we continued to use a universal two-step
screening strategy for GDM in our hospital with a non-fasting 50g glucose challenge test
(GCT) (performed at the hospital or in primary care) between 24–28 weeks of pregnancy.
Those testing positive [threshold after 1-h 140 mg/dl (7.8 mmol/l)] had a 2-h 75-g OGTT in
the hospital at 24–28 gestational weeks using the 2013 WHO criteria for GDM [fasting plasma
glycaemia (FPG) 92 mg/dl (5.1 mmol/l), 1-h glycaemia 180 mg/dl (10.0 mmol/l), 2-h
glycaemia 153 mg/dl (8.5 mmol/l), diagnosis of GDM if 1 values is abnormal] [4]. There
are no specific recommendations in our center on which women should receive screening for
GDM before 24 weeks of pregnancy. Screening for GDM with a GCT is sometimes performed
before 24 weeks of pregnancy in high risk women such as women with a history of GDM. As
part of an ongoing study evaluating the one-step approach with a 75g OGTT using the 2013
WHO criteria, some women received the 75g OGTT irrespective of the GCT result [12].
Women with GDM were treated with insulin when despite lifestyle measures the FPG
was 95 mg/dl (5.3 mmol/l) and/or 2-hour postprandial glycaemia120 mg/dl (6.7 mmol/l).
Oral anti-diabetes drugs such as metformin and glibenclamide (glyburide) are not routinely
used during pregnancy in our hospital. Our primary goal was to evaluate the prevalence of glu-
cose intolerance in early postpartum since the implementation of the 2013 WHO criteria for
the diagnosis of GDM in our hospital. A formal power calculation was therefore not
performed.
Follow up postpartum
In our center women with a previous diagnosis of GDM are recommended to receive a 2 hour
75g OGTT three months after the delivery. Women receive an appointment for the postpartum
OGTT at the delivery and a reminder is send with a SMS text message using an automatic elec-
tronic system within two weeks before the scheduled appointment. If women do not attend the
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scheduled postpartum OGTT, the diabetes nurse will try to reach women once more by tele-
phone to make a new appointment. As part of the normal routine in our hospital, the OGTT is
generally postponed to max. 6 months postpartum If women are still breastfeeding at 3 months
postpartum.
Registration of characteristics and pregnancy outcomes
Outcomes were obtained from review of the electronic database. Maternal characteristics
recorded were age, weight, body mass index (BMI) at first prenatal visit and at delivery, over-
weight (BMI25 Kg/m2), obesity (BMI30 Kg/m2), weight gain (difference in weight
between first prenatal visit and the delivery), ethnicity, parity, smoking and alcohol habits, fam-
ily history of diabetes, history of GDM, history of polycystic ovary syndrome, hypertension,
dyslipidemia and glucose intolerance before pregnancy. Excessive weight gain was defined
according to the most recent Institute of Medicine (IOM) guidelines, except for obese women
for whom we use the recommendation to gain 5Kg during pregnancy [13]. Other data that
were recorded are: whether or not the scheduled postpartum OGTT was attended, the timing
of the OGTT postpartum, the glucose values and the insulin values based on the 75g OGTT
postpartum (0min-30min-60min-120min) and the glucose values based on the 75g OGTT dur-
ing pregnancy (0min-60min-120min), whether women breastfed or not, gestational age at
delivery, the timing and result of the GCT, the gestational age at the diagnosis of GDM, HbA1c
at the time of the 75g OGTT during pregnancy, whether women received treatment with corti-
coids during pregnancy after the screening test, need of insulin, type of insulin and number of
injections and the gestational age at the start of insulin. There are no data in our database on
how long or how exclusive breastfeeding was given.
The following maternal pregnancy outcomes were recorded: gestational hypertension
(blood pressure 140/90mmHg), preeclampsia [hypertension with proteinuria or in combina-
tion with reduced fetal growth or the ‘Hemolysis Elevated Liver enzymes and Low Platelets’
(HELPP)-syndrome], preterm delivery (<37 weeks of gestation) and cesarean section (planned
+ emergency sections combined). The following neonatal outcomes were recorded: birth
weight, macrosomia (birth weight> 4kg), large-for-gestational age infants (LGA, birth weight
>90 percentile adjusted for sex and parity according to the Flemish birth charts), small-for-
gestational age infants (SGA, birth weight<10 percentile adjusted for sex and parity according
to the Flemish birth charts), shoulder dystocia, Apgar score< 7 at five minutes and admission
at the neonatal intensive care unit (NICU).
Definition of (pre)diabetes
To define glucose intolerance postpartum, the criteria of the American Diabetes Association
were used: diabetes was defined as FPG126mg/dl (7.0mmol/l) and/or 2-hour glycaemia at
the OGTT postpartum200mg/dl (11.1mmol/l)] and prediabetes was defined as impaired
fasting glucose (IFG) with a FPG100-125mg/dl (5.5–6.9mmol/l) and/or impaired glucose
tolerance (IGT) with a 2-hour glycaemia at the OGTT postpartum140-199mg/dl (7.8–
11.0mmol/l) [1].
Insulin sensitivity and beta-cell function
Insulin sensitivity was measured using the insulin sensitivity index of Matsuda, a well-estab-
lished measure of whole-body insulin sensitivity [14]. The insulin sensitivity index of Matsuda
is defined as 10 000/
p
[(FPG x fasting plasma insulin) X (mean glucose during OGTT x mean
insulin during OGTT)] [15]. As a secondary measure of insulin sensitivity (largely hepatic), we
also calculated the reciprocal of the homeostasis model assessment of insulin resistance
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(1/HOMA-IR) [15]. HOMA-IR is calculated as the product of FPG and fasting plasma insulin
divided by 22.5 [15]. Beta-cell function was assessed by the insulinogenic index dived by
HOMA-IR. The insulinogenic index was calculated as the incremental change in insulin con-
centration during the first 30 min of the OGTT divided by the incremental change in glucose
during the same period [16,17]. As a secondary measure of beta-cell function, the insulin secre-
tion sensitivity index (ISSI-2) was measured, an OGTT-derived measure that is analogous to
the disposition index obtained from the frequently sampled intravenous glucose tolerance test
[18,19]. Glycaemia was assessed by the area under the glucose curve during the OGTT, calcu-
lated using the trapezoidal rule [18,19]. ISSI-2 is defined as the product of 1) insulin secretion
measured by the ratio of the area under the insulin curve to the area under the glucose curve
and 2) insulin sensitivity measured by the insulin sensitivity index of Matsuda [18,19]. All
these measures have been validated for use in women with GDM.
Until October 2015 HbA1c was measured by a reversed-phase cation-exchange chromatog-
raphy (ADAMS HA-8160, Menarini Diagnostics Benelux, Zaventem, Belgium). Since October
2015 HbA1c was measured by a high performance liquid chromatography principle with the
cationic non-porous ion exchanger using the ionic difference (Tosoh HLC-723G8, Tessendrlo,
Belgium). In our center Hba1c is reported in compliance with the National Glycohemoglobin
Standardization Program since 1996. Plasma glucose was measured by an automated colori-
metric-enzymatic method (hexokinase-glucose-6-phosphate-dehydrogenase, application 668)
on a Hitachi/Roche-Modular P analyzer. Insulin was measured by the immunometric ECLIA
(Roche Modular E170, Basel, Switserland).
Statistical Analyses
Statistical analyses were performed using SPSS 22.0. Continuous data were expressed as mean
and standard deviation if normally distributed, non-parametric variables were expressed as
median. Categorical data were expressed as percentage. To compare variables between two
groups independent samples t-tests were used for normally distributed continuous variables,
Mann–Whitney’s U-test for non-parametric variables and chi-squared tests for categorical var-
iables. Multivariable logistic regression was used to analyse independent predictors for glucose
intolerance postpartum. Due to a limited number of events, we used a max. number of 5 vari-
ables per multivariable regression model. We therefore analyzed the effect of each variable of
interest in a separate model, including also age, BMI, ethnicity and breastfeeding as possible
confounders. Multivariable logistic regression was also used to evaluate the impact of possible
confounders on insulin sensitivity and beta-cell function. A p-value of<0.05 (two-tailed) was
considered significant.
Results
Over a period of 23 months, 211 women were identified with a recent history of GDM. After
evaluation of the medical files, 20 files were not included in the analysis because women did
not deliver in our center (10) or because they had not yet received the postpartum OGTT
because they were not yet 3 months postpartum (10), leaving a cohort of 191 women with a
recent history of GDM for analysis. Over this time period the prevalence of GDM was 5.5%.
Overall, 49.5% of women had an FPG diagnostic for GDM using the 2013 WHO criteria.
The mean age of the cohort was 31.7 years (±4.8), 14.1% had a history of GDM, 9.9% had a
history of hypertension, 6.3% had a history of prediabetes, 29.6% were overweight and 28.0%
were obese at the first prenatal visit. Of all women 29.8% had a EM background. The most fre-
quent EM background was Middle-Eastern in 11.5%, Black African in 6.8%, South Asian in
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6.8% and Northern-African in 3.7%. The median week at diagnosis of GDM was 27.0 (25.0–
28.0) and 23.2% of women needed insulin during pregnancy.
Mean gestational age at delivery was 38.1 ±2.2 weeks. Analysis of pregnancy outcomes
showed that 6.3% had a LGA baby, 3.1% had macrosomia, 11.0% had a SGA baby, 13.6% had
gestational hypertension, 4.7% had preeclampsia, 18.3% had a preterm delivery, 2.1% had
shoulder dystocia, 4.2% had low Apgar scores, 15.2% was admitted at NICU and 34.0% was
delivered by cesarean section.
Postpartum screening was offered to all women but 29.3% (56) did not attend the scheduled
postpartum OGTT. Compared to women who received an OGTT postpartum, women who
did not attend the postpartum OGTT, had a higher BMI (28.6 ±6.8 vs. 26.2 ± 5.6, p = 0.015),
were more often from a EM background (41.1% vs. 25.2%, p = 0.029) and smoked more often
during pregnancy (14.3% vs. 2.2%, p = 0.001) [Table 1].
The postpartum OGTT was performed at a median of 14.0 weeks (13.0–15.0). Of all women
(135) who received an OGTT postpartum, 42.2% (57) had prediabetes (11.9% IFG, 24.4% IGT
and 5.9% both IFG and IGT combined) and 1.5% (2) had overt diabetes. Compared to women
with a normal OGTT postpartum, women with glucose intolerance were older (32.5±4.3 vs.
30.8±4.8 years, p = 0.049), were more often obese (34.5% vs. 17.3%, p = 0.023), had more often
excessive weight gain during pregnancy (44.8% vs. 25.3%, p = 0.018), were more often from an
Table 1. Comparison of the characteristics between womenwho received an OGTT postpartum and womenwho failed to attend the scheduled
OGTT post-partum.
Women with OGTT postpartum N = 135
(70.7%)
Women without OGTT postpartum N = 56
(29.3%)
p-value
Age (mean) 31.5±4.6 32.2±5.8 0.370
BMI at ﬁrst prenatal visit (mean) 26.2±5.6 28.6±6.8 0.015
% overweight at ﬁrst prenatal visit 28.6% 32.1% 0.623
% obese at ﬁrst prenatal visit 24.8% 35.7% 0.128
% excessive weight gain 33.8% 48.2% 0.063
% EM 25.2% 41.1% 0.029
% smoking before pregnancy 6.7% 17.9% 0.019
% smoking during pregnancy 2.2% 14.3% 0.001
% ﬁrst degree family member with T2DM 11.9% 19.6% 0.362
% history of GDM 13.3% 16.1% 0.257
% hypertension before pregnancy 10.4% 8.9% 0.762
% prediabetes before pregnancy 5.2% 8.9% 0.181
% multiparous 60.0% 67.9% 0.308
% breastfeeding 77.8% 78.6% 0.904
Week OGTT 27.0(26.0–28.0) 26.5(25.0–28.0) 0.515
% fasting abnormal on the OGTT in
pregnancy
45.0% 60.4% 0.059
% 2 values abnormal on the OGTT in
pregnancy
40.3% 48.1% 0.328
% 3 values abnormal in pregnancy 9.3% 18.5% 0.080
% insulin 23.1% 23.2% 0.990
Weeks start insulin (median) 29.0(27.0–30.5) 28.0(20.0–30.5) 0.494
GDM: gestational diabetes; OGTT: oral glucose tolerance test; EM: Ethnic Minority Backgrounds; T2DM: type 2 diabetes; Statistical analyzes: for normally
distributed continuous variables the independent samples t-tests were used and chi-squared tests were used for categorical variables. P values in bold
are statistical signiﬁcant.
doi:10.1371/journal.pone.0157272.t001
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EM background (33.9% vs. 18.4%, p = 0.040), less often breastfed (69.5% vs. 84.2%, p = 0.041)
and had more often an abnormal fasting glycaemia (55.6% vs. 37.3%, p = 0.040) and higher
median HbA1c [(5.1% (5.0–5.4) vs. 5.0%(4.8–5.2), p = 0.001] at the time of the OGTT
[Table 2]. In the multivariable logistic regression, an EM background [OR = 2.76 (1.15–6.62),
p = 0.023] and the HbA1c level at the time of the OGTT in pregnancy [OR = 4.78 (1.19–19.20),
p = 0.028] remained significant independent predictors for glucose intolerance postpartum
after adjustment for BMI, ethnicity, age and breastfeeding [Table 3].
Compared to women with a normal OGTT postpartum, women with glucose intolerance
postpartum had a similar insulin sensitivity but a lower beta-cell function, remaining signifi-
cant after adjustment for confounders [ISSI-2 1.6 (1.2–2.1) vs. 1.9 (1.7–2.4),p = 0.002]
[Table 4].
Compared to women with IGT postpartum, women with IFG, were more often obese
(62.6% vs. 21.9%, p = 0.006), had less often a history of GDM (14.1% vs. 21.2%, p = 0.047), had
a lower GCT value and a higher fasting but lower 2 hour value at the OGTT in pregnancy
[Table 5]. There were no differences between both groups in insulin sensitivity and beta-cell
function [Table 6].
Table 2. Comparison of the characteristics between womenwith a normal OGTT and women with glucose intolerance postpartum.
Normal N = 76 (56.3%) Glucose intolerance N = 59 (43.7%) p-value
Age (mean) 30.8±4.8 32.5±4.3 0.049
BMI at ﬁrst prenatal visit (mean) 25.4±5.5 27.2±5.6 0.069
% overweight at ﬁrst prenatal visit 30.7% 25.9% 0.543
% obese at ﬁrst prenatal visit 17.3% 34.5% 0.023
% excessive weight gain 25.3% 44.8% 0.018
Weight gain in Kg (mean) 15.0± 1.7 15.4±2.0 0.658
% EM 18.4% 33.9% 0.040
% smoking before pregnancy 5.3% 8.5% 0.458
% ﬁrst degree family member with T2DM 11.8% 11.9% 0.984
% history of GDM 13.2% 13.6% 0.946
% history of hypertension 6.6% 15.3% 0.101
% history of prediabetes 3.9% 6.8% 0.462
% multiparous 60.5% 59.3% 0.887
% breastfeeding 84.2% 69.5% 0.041
Week of GCT (median) 25.5(24.2–26.2) 25.0(24.0–26.7) 0.671
Result GCT mg/dl (median) 153.0(144.0–174.0) 169.0(153.5–187.5) 0.059
Week OGTT (median) 153.0 (144.0–174.0) 26.2(25.0–27.6) 0.140
% fasting abnormal on the OGTT in pregnancy 37.3% 55.6% 0.040
% 1 hour abnormal on the OGTT in pregnancy 48.0% 40.7% 0.414
% 2 hour abnormal on the OGTT in pregnancy 62.7% 53.7% 0.307
% 2 values abnormal on the OGTT in pregnancy 40.0% 40.7% 0.933
% 3 values abnormal on the OGTT in pregnancy 9.3% 9.3% 0.989
HbA1c % [mmol/mol] at time of OGTT (median) 5.0%(4.8–5.2) [31(29–33)] 5.1%(5.0–5.4) [32(31–36)] 0.001
% insulin 18.7% 28.8% 0.167
Weeks start insulin (median) 29.2(27.7–31.0) 28.0(25.0–30.2) 0.316
GDM: gestational diabetes; OGTT: oral glucose tolerance test; GCT: glucose challenge test; EM: Ethnic Minority Backgrounds; T2DM: type 2 diabetes;
Statistical analyzes: for normally distributed continuous variables the independent samples t-tests were used, for non-parametric variables the Mann–
Whitney’s U-test and for categorical variables the chi-squared tests. P values in bold are statistical signiﬁcant.
doi:10.1371/journal.pone.0157272.t002
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Discussion
There is uncertainty about how detection of GDM using the 2013 WHO criteria influences the
longer term risk of developing T2DM in women. The use of the 2013 WHO criteria for GDM
results in a greater proportion of women diagnosed with mild forms of GDM which might pre-
sumably lead to a lower proportion at risk for postpartum glucose intolerance. Previous studies
Table 3. Independent predictors of glucose intolerance postpartum.
Variable Degrees of freedom Standard Error OR (95% CI) p-value
age 1 0.43 1.07(0.98–1.16) 0.123
BMI 1 0.036 1.04(0.97–1.12) 0.218
EM 1 0.45 2.76(1.15–6.62) 0.023
breastfeeding 1 0.47 0.44 (0.17–1.11) 0.082
excessive gestational weight gain 1 0.44 2.26(0.96–5.35) 0.062
Smoking 1 0.79 1.39(0.26–6.59) 0.677
ﬁrst degree family member with T2DM 1 0.61 0.91(0.28–2.99) 0.877
history of GDM 1 0.59 0.74(0.23–2.4) 0.739
history of hypertension 1 0.65 2.35(0.66–8.42) 0.188
history of prediabetes 1 0.87 0.97(0.18–5.31) 0.971
multiparity 1 0.44 0.53(0.22–1.25) 0.149
Week of GCT 1 0.20 0.85(0.57–1.27) 0.426
Result GCT 1 0.01 1.01(0.98–1.03) 0.525
Week OGTT 1 0.06 0.94(0.83–1.06) 0.287
Fasting glycaemia on OGTT in pregnancy 1 0.02 1.03(0.98–1.07) 0.240
1h glycaemia on OGTT in pregnancy 1 0.01 1.00(0.99–1.01) 0.559
2h glycaemia on OGTT in pregnancy 1 0.01 0.99(0.98–1.00) 0.125
2 values abnormal on the OGTT in pregnancy 1 0.40 0.71(0.32–1.57) 0.397
3 values abnormal on the OGTT in pregnancy 1 0.68 0.64(0.17–2.44) 0.518
HbA1c at time of OGTT in pregnancy 1 0.71 4.78(1.19–19.20) 0.028
insulin 1 0.47 1.16(0.46–2.93 0.753
Weeks start insulin 1 0.11 0.97(0.78–1.21) 0.801
GDM: gestational diabetes; OGTT: oral glucose tolerance test; GCT: glucose challenge test; EM: Ethnic Minority Backgrounds; T2DM: type 2 diabetes;
Multivariable logistic regression with odds ratio (OR) adjusted for age, BMI, ethnicity and breastfeeding. Data are presented as OR (95% CI lower-upper
limit). P values in bold are statistical signiﬁcant.
doi:10.1371/journal.pone.0157272.t003
Table 4. Comparison of the beta-cell function and insulin sensitivity between women with a normal OGTT and womenwith glucose intolerance
postpartum.
Normal N = 76 (56.3%) Glucose intolerance N = 59 (43.7%) P value Adjusted p value
ISSI-2 index (median) 1.9(1.7–2.4) 1.6(1.2–2.1) <0.0001 0.002
Insulinogenic index/HOMA-IR index (median) 0.010(0.008–0.014) 0.009(0.005–0.015) 0.119 0.249
Matsuda index (median) 0.778(0.532–1.067) 0.656(0.386–1.224) 0.279 0.709
1/HOMA-IR index(median) 0.004(0.003–0.007) 0.004(0.002–0.009) 0.699 0.384
ISSI-2: insulin secretion sensitivity index postpartum; Insulinogenic index/HOMA-IR is a measure for beta-cell function postpartum; Matsuda: insulin
sensitivity index of Matsuda postpartum; 1/HOMA-IR: the reciprocal of the homeostasis model assessment of insulin resistance post-partum; Statistical
analyzes: for non-parametric variables the Mann–Whitney’s U-test were used. The p-values for the measurements post-partum are adjusted for age, BMI,
ethnicity and breastfeeding. P values in bold are statistical signiﬁcant.
doi:10.1371/journal.pone.0157272.t004
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Table 5. Comparison of characteristics between womenwith an impaired fasting glucose (IFG) and womenwith an impaired glucose tolerance
(IGT) postpartum.
IFG N = 16 (32.7%) IGT N = 33 (67.3%) p-value
Age (mean) 32.0±5.3 33.5±3.6 0.255
BMI at ﬁrst prenatal visit (median) 31.3±4.4 25.2±4.8 <0.0001
% overweight at ﬁrst prenatal visit 37.5% 21.9% 0.251
% obese at ﬁrst prenatal visit 62.6% 21.9% 0.006
% excessive weight gain 68.8% 34.4% 0.024
% EM 25.0% 39.4% 0.321
% ﬁrst degree family member with T2DM 18.8% 12.1% 0.659
% history of GDM 14.1% 21.2% 0.047
% hypertension before pregnancy 12.5% 9.1% 0.712
% prediabetes before pregnancy 0 9.1% 0.213
% multiparous 50.0% 60.6% 0.482
% breastfeeding 68.8% 69.7% 0.946
% progestin-only oral contraceptive 69.2% 44.4% 0.380
Week of GCT (median) 25.5(24.6–27.1) 25.0(24.0–27.5) 0.667
Result GCT (median) 147.0(120.7–163.5) 170.0(156.0–192.0) 0.016
Week OGTT (median) 27.0(24.0–30.5) 26.0(25.0–27.1) 0.177
% fasting abnormal on the OGTT in pregnancy 80.0% 43.3% 0.020
% 1h abnormal on the OGTT in pregnancy 40.0% 40.0% 1.000
% 2h abnormal on the OGTT in pregnancy 33.3% 66.7% 0.034
% 2 values abnormal on the OGTT in pregnancy al 40.0% 46.7% 0.671
% 3 values abnormal on the OGTT in pregnancy 13.3% 3.3% 0.205
Median FPG on the OGTT in pregnancy 95.0(93.0–101.0) 90.5(81.0–92.0) 0.012
Median 1 hour glycaemia on the OGTT in pregnancy 150.0(138.0–205.0) 172.0(163.7–196.0) 0.306
Median 2 hour glycaemia on the OGTT in pregnancy 115.0(110.0–158.0) 158.0(144.2–166.2) 0.006
% insulin 31.3% 21.2% 0.444
Weeks start insulin (median) 28.0(20.5–32.5) 29.0(27.0–31.0) 0.530
Eight women with the combination of IFG and IGT were excluded from these analyses. GDM: Gestational diabetes; OGTT: oral glucose tolerance test;
GCT: glucose challenge test; FPG: fasting plasma glycaemia; EM: Ethnic Minority Backgrounds; T2DM: type 2 diabetes; Statistical analyzes: for normally
distributed continuous variables the independent samples t-tests were used, for non-parametric variables the Mann–Whitney’s U-test and for categorical
variables the chi-squared tests. P values in bold are statistical signiﬁcant.
doi:10.1371/journal.pone.0157272.t005
Table 6. Comparison of the beta-cell function and the insulin sensitivity between women with an impaired fasting glucose (IFG) and women with
an impaired glucose tolerance (IGT) postpartum.
IFG N = 16 (32.7%) IGT N = 33 (67.3%) P value Adjusted p value
ISSI-2 index (median) 1.7(1.1–2.2) 1.6(1.3–2.1) 0.890 0.610
Insulinogenic index/HOMA-IR index (median) 0.007 (0.004–0.015) 0.011 (0.006–0.017) 0.363 0.831
Matsuda index (median) 0.441 (0.356–1.527) 0.696 (0.414–1.160) 0.396 0.977
1/HOMA-IR (median) 0.003 (0.002–0.007) 0.005 (0.002–0.009) 0.209 0.737
Eight women with the combination of IFG and IGT were excluded from these analyses. IFG: impaired fasting glucose; IGT: impaired glucose tolerance;
ISSI-2: insulin secretion sensitivity index postpartum; Insulinogenic index/HOMA-IR is a measure for beta-cell function postpartum; Matsuda: insulin
sensitivity index of Matsuda postpartum; 1/HOMA-IR: the reciprocal of the homeostasis model assessment of insulin resistance post-partum; Statistical
analyzes: for non-parametric variables the Mann–Whitney’s U-test were used. The p-values for the measurements post-partum are adjusted for age, BMI,
ethnicity and breastfeeding. P values in bold are statistical signiﬁcant.
doi:10.1371/journal.pone.0157272.t006
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have evaluated the risk of postpartum glucose intolerance in women with a diagnosis of GDM
based on a universal one-step approach with a 75g OGTT and the 2013 WHO criteria [20,21].
The use of the 2013 WHO criteria for GDM in a two-step screening strategy with a GCT is
used as a practical solution so that the number of OGTTs can be limited but this has not yet
been validated. Data on the sensitivity and specificity of a GCT in combination with a 75g
OGTT and the 2013 WHO criteria are lacking. Ongoing studies such as the Belgian Diabetes in
Pregnancy study (BEDIP-N) are currently evaluating the 2013 WHO criteria in a multiethnic
Belgian cohort comparing a universal one-step, a two-step with a GCT and a risk factor based
screening approach [12]. Data on the risk of glucose intolerance in early postpartum in women
with GDM diagnosed with the two-step screening strategy and the 2013 WHO criteria are
therefore needed. We show now similar high rates of glucose intolerance with the 2013 WHO
criteria as with the Carpenter and Coustan criteria in early postpartum in our population [22].
In our cohort with GDM based on the 2013 WHO criteria, 42.2% had prediabetes (11.9% IFG,
24.4% IGT and 5.9% both IFG and IGT combined) and 1.5% had overt diabetes in early post-
partum. We have previously reported that when using the 100g OGTT and the Carpenter and
Coustan criteria for GDM in our population, 39.1% had prediabetes and 5.3% had diabetes in
early postpartum [23]. The high prevalence of glucose intolerance in early postpartum using
the Carpenter and Coustan criteria for GDM is to be expected since these criteria were devel-
oped to identify women at high risk for the development of T2DM after the delivery [22]. On
the other hand, the IADPSG/2013 WHO criteria are the first diagnostic criteria for GDM
based on the risk for adverse pregnancy outcomes. Adverse pregnancy outcomes in our study
were low with LGA rates of 6.3% and macrosomia rates of 3.1%. Recent analysis of pregnancy
outcomes in our center in women with GDM diagnosed with the Carpenter and Coustan crite-
ria showed much higher LGA and macrosomia rates (resp. 16.9% and 8.7%) [24]. This is in
line with previous studies showing lower adverse pregnancy outcomes in women treated for
GDM based on the 2013 WHO criteria compared to the Carpenter and Coustan criteria [25].
In our study 23.2% of women needed treatment with insulin during pregnancy. This is in line
with a large Spanish cohort study showing similar rates of insulin use (around 20%) in women
with GDM based on the 2013 WHO criteria [25].
Our study shows much higher rates of glucose intolerance in early postpartum compared to
studies in Irish women where a rate of prediabetes and diabetes of 19% was reported in women
with GDM based on the 2013 WHO criteria in the first year postpartum and this increased to
25% in the same cohort when re-screened up to 5 years post-delivery [20,21]. This may be
related to differences in population characteristics since only 13.6% of the Irish women had an
EM background while this was 29.8% in our study. The main difference is probably related to
the screening strategy used for GDM. In the Irish studies a universal one-step approach with a
75g OGTT was used while in our center a universal two-step screening strategy with a GCT
was used which might identify women at higher risk for the development of glucose intolerance
postpartum. Previous studies have shown that any degree of abnormal glucose homeostasis in
pregnancy independently predicts an increased risk of glucose intolerance and that women
with GDM, with gestational impaired glucose tolerance or with an abnormal GCT but normal
OGTT have varying rates of declining beta-cell function with a progressive decline of beta-cell
function over time across the different groups [26,27]. GDM women diagnosed in a two-step
screening strategy fail both the GCT and OGTT test and this might therefore identify women
with a lower underlying beta-cell function compared to women with mild GDM detected by
OGTT only. Our study shows that compared to women with a normal OGTT, women with
glucose intolerance had a similar insulin sensitivity but a lower beta-cell function postpartum,
which remained significantly lower after adjustment of confounders such as age, BMI, ethnicity
and breastfeeding.
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Of all women with prediabetes, 57.9% had IGT, 28.1% had IFG and 14.0% had IFG and IGT
combined. A FPG alone postpartum would therefore have missed the majority of women with
glucose intolerance, confirming the need for an OGTT in early postpartum in our population.
This is in contrast with the most recent British guidelines of the ‘National Institute for Health
and Care Excellence’ (NICE) stating that a 75g OGTT should not be routinely offered for
women with a history of GDM and instead recommending the use of a fasting glucose in early
postpartum [28]. Studies evaluating the use of HbA1c alone or in combination with FPG to
diagnose glucose intolerance in women who have had GDM, show conflicting results with sen-
sitivity rates of HbA1c and FPG combined ranging from 83.0% to 90.0% [21,29].
The most important risk factors to develop glucose intolerance in early postpartum differ
according to the populations studied [30]. The most common risk factors are maternal age,
pre-pregnancy weight, early GDM diagnosis, insulin treatment during pregnancy and the FPG
on the diagnostic OGTT during pregnancy [30]. In our study, only an EM background and the
HbA1c level at the time of diagnosis of GDM remained independent predictors of glucose
intolerance after adjustment for confounders. Breastfeeding has been associated with lower
FPG and insulin, and a lower prevalence of glucose intolerance 6–9 weeks post-partum [21,31].
The majority of women were breastfeeding in our cohort. Compared to women with a normal
OGTT postpartum, fewer women were breastfeeding in the group with glucose intolerance.
However, in the multivariable regression analysis, breastfeeding was not an independent pre-
dictor for glucose intolerance. This might be due to the lack of data in our database on how
long or how exclusive women were effectively breastfeeding postpartum.
We also show that compared to women with IGT postpartum, women with IFG are more
often obese and have a higher FPG at the time of the OGTT in pregnancy. We have previously
shown that after a diagnosis of GDM with the Carpenter and Coustan criteria women with IFG
in early postpartum, have a lower insulin sensitivity compared to women with IGT and this
seems to be largely driven by a higher BMI [23]. In current study, there were no differences
between both groups in insulin sensitivity and beta-cell function. This might be related to the
smaller sample size and the use of the 2013 WHO criteria for GDM diagnosing more milder
forms of GDM.
In our study nearly one third of women did not attend the scheduled OGTT postpartum.
This is higher than the non-attendance rate of 21% we have previously reported in women
with GDM based on the Carpenter and Coustan criteria [23]. More efforts are clearly needed
to better inform and engage women to attend the postpartum test since despite the use of a an
automatic electronic system that triggers postpartum SMS reminders and if needed a tele-
phonic recall done by a diabetes nurse, the attendance rate seems to decrease. Especially
women with an EM background have a high non-attendance rate in our study while we show
that these women are at particular high risk for glucose intolerance in early postpartum. Many
studies have reported even lower postpartum testing rates with only 30–50% of women with
recent GDM who receive an OGTT within 6 months after the delivery [32,33]. This is a missed
opportunity in a high-risk population to timely detect glucose intolerance and start lifestyle
interventions to prevent or delay the development of glucose intolerance and diabetes [8].
Strengths of the study are the detailed characterization of a relatively large cohort of women
with recent GDM based on a two-step screening strategy and the 2013 WHO criteria using a
good database. A multivariable regression analysis was used to evaluate independent predictors
of glucose intolerance postpartum. Multiple measures of beta-cell function and insulin sensitiv-
ity were calculated and adjusted for confounders. A limit of the study is the retrospective nature
of the analysis and the lack of longer term data postpartum on the risk for glucose intolerance.
We have no data on the HbA1c level postpartum and on weight loss of women postpartum,
both possible predictors of glucose intolerance.
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In conclusion, we show that glucose intolerance is very frequent in early postpartum in
women with GDM based on the 2013 WHO criteria in a two-step screening strategy and these
women have an impaired beta-cell function. Nearly one third of women did not attend the
scheduled OGTT postpartum. More efforts are needed to engage and stimulate women with
GDM to attend the postpartum OGTT.
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